ADTX — Aditxt Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.78 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 11 | 42.42 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +309.09 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aditxt, Inc., formerly Aditx Therapeutics, Inc., is a biotechnology company. The Company is developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming. The Company’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The company’s technology platforms include AditxtScore and AditxtReprogramming. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assist the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. Apoptotic DNA Immunotherapy (ADi) is a nucleic acid-based technology which suppresses only those immune cells involved in the rejection of tissue and organ transplants.
Directors
- Amro Albanna (50)
- Corinne Pankovcin (54)
- Rowena Albanna (54)
- Shahrokh Shabahang (57)
- Jeffrey Runge LED
- Lauren Chung (48)
- Laura Anthony (51)
- Brian Brady (41)
- Namvar Kiaie (54)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- September 28th, 2017
- Public Since
- January 1st, 1970
- No. of Shareholders
- 135
- No. of Employees
- 43
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 14,546,248
- Address
- 737 N. Fifth Street, Suite 200, RICHMOND, 23219
- Web
- https://aditxt.com/
- Phone
- +1 9094880844
- Auditors
- dbbmckennon
Latest News for ADTX
Upcoming events for ADTX
Similar to ADTX
180 LIFE SCIENCES ORD
NASDAQ Capital Market
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in Aditxt are trading at $1.80. This share price information is delayed by 15 minutes.
Shares in Aditxt last closed at $1.80 and the price had moved by -60.78% over the past 365 days. In terms of relative price strength the Aditxt share price has underperformed the S&P500 Index by -70.25% over the past year.
The overall consensus recommendation for Aditxt is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aditxt does not currently pay a dividend.
Aditxt does not currently pay a dividend.
Aditxt does not currently pay a dividend.
To buy shares in Aditxt you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.80, shares in Aditxt had a market capitalisation of $26.18m.
Here are the trading details for Aditxt:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADTX
Based on an overall assessment of its quality, value and momentum Aditxt is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Aditxt is $14.00. That is 677.78% above the last closing price of $1.80.
Analysts covering Aditxt currently have a consensus Earnings Per Share (EPS) forecast of $0.22 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aditxt. Over the past six months, its share price has underperformed the S&P500 Index by -62.44%.
As of the last closing price of $1.80, shares in Aditxt were trading -31.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aditxt.
Aditxt's management team is headed by:
- Amro Albanna -
- Corinne Pankovcin -
- Rowena Albanna -
- Shahrokh Shabahang -
- Jeffrey Runge - LED
- Lauren Chung -
- Laura Anthony -
- Brian Brady -
- Namvar Kiaie -
We do not have data on Aditxt's shareholders